About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Accenture Helping Astellas Pharma Create Next-Generation Cloud-Based IT Core Platform for Advanced Real-Time Decision Making

By: via Business Wire

New platform supports sustainable and innovative medical solutions through centralized data visualization across global operations

Accenture (NYSE: ACN) helped Astellas Pharma Inc. create a cloud-based core IT platform that serves as the foundation for an advanced, data-driven management model for the company’s global operations. The new platform has been rolled out in Japan, the Americas and EMEA, with plans for further deployments.

The flexibility of the cloud enables Astellas to rapidly incorporate new and emerging technologies, accommodate business expansions such as mergers and acquisitions, and quickly deploy business continuity plans.

Based on SAP S/4HANA® and running on Microsoft Azure, the new platform will consolidate and integrate data from Astellas’ supply chain, human resources and purchasing and accounting operations into a single view. Previously, this data was spread across countries, locations and departments.

It also includes SAP® SuccessFactors® solutions, human capital management software, that rather than solely focusing on transactional HR processes is designed to enhance employee productivity and agility globally to drive innovation.

This represents a step forward for Astellas to build an “enterprise digital twin,” which can simulate, predict and model the dynamic functions of an entire organization to explore potential business opportunities and highlight potential risk factors. This will enable Astellas to visualize information in a centralized manner to enhance decision-making.

In parallel with the development and implementation of the new platform, Accenture is delivering business process services to strengthen the agility of Astellas' global-scale operations. The data gathered by the new IT platform and operations services will be combined with digital technologies, such as artificial intelligence, robotic process automation and analytics to streamline its enterprise processes. This should help Astellas optimize sales and administrative expenses; accelerate efforts to expand its research capabilities; and foster greater innovation —ultimately enabling the company to generate additional resources for drug discovery.

“We were able to move to a full-cloud platform with the help of Accenture, which has extensive experience in implementing core platforms for global operations,” said Shinya Suda, senior vice president and head of Information Systems at Astellas. “The success of the project was due to Accenture's ability to bring together a wide range of experts from around the world for a truly ‘one-team’ approach with Astellas. We can centralize data and make the best use of this technology to create a business platform that supports visualization and bold data-driven decision-making. In collaboration with Accenture and other internal and external partners, Astellas will continue to focus on creating innovations that contribute to the health of people around the world.”

Motoki Fujita, vice president and head of Global Business Services at Astellas, added, “The new platform will accelerate our Global Business Service efforts to integrate operations on a global scale. This will create an environment that contributes to the business by optimizing selling and administrative expenses and creating an environment that allows employees to focus on high value-added work. We will leverage AI, RPA, and other digital technologies to thoroughly visualize and automate operations, and drive toward the goal of Intelligent Operation.”

Mitsuru Nagata, Senior Managing Director and Intelligent Platform Services lead for Accenture Technology in Japan, said, “I am pleased to be able to support this significant project that will accelerate the ‘One Astellas’ vision. By bringing together the talent of both companies from around the world and thanks to the strong commitment of Astellas' top management to complete the project we were able to set up this core platform. Accenture will continue to support Astellas' innovation efforts by leveraging our deep knowledge of the life sciences industry and our global network.”

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 674,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at accenture.com.

Accenture’s Life Sciences industry group helps pharmaceutical, biotech, medical technology. distributor and consumer health companies combine the latest technology with scientific breakthroughs to revolutionize how medical treatments are discovered, developed and delivered to patients around the world. To learn more, visit https://www.accenture.com/us-en/industries/life-sciences-index.

This content is provided for general information purposes and is not intended to be used in place of consultation with our professional advisors. This document refers to marks owned by third parties. All such third-party marks are the property of their respective owners. No sponsorship, endorsement or approval of this content by the owners of such marks is intended, expressed or implied.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.

Copyright © 2022 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.

Contacts

More News

View More
Why the Precious Metal Nobody Talks About Could Be Your Best Bet
Via MarketBeat
Topics ETFs Economy
Tickers PALL VOO
Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
Via MarketBeat
Tickers CMG YUM
3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Via MarketBeat
Topics Economy Stocks World Trade
Tickers CC DOW NUE
A Copper Catalyst: Why Freeport-McMoRan Is Positioned to Rebound
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers BAC FCX
MarketBeat Week in Review – 09/29 - 10/03
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers AAPL APP BBAI BYDDF COST CRWV
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.